Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Sara A. Hurvitz, MD, on Evaluating Biomarkers in Triple-Negative Breast Cancer

Posted: Tuesday, January 5, 2021

Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses findings from the ASCENT study, including analyses of biomarkers and whether they may be useful in selecting patients or guiding therapy with sacituzumab govitecan vs chemotherapy for patients with metastatic triple-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.